Contrasting TNF Pharmaceuticals (NASDAQ:TNFA) and Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ:VRAX) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

8.6% of Virax Biolabs Group shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 45.1% of Virax Biolabs Group shares are owned by company insiders. Comparatively, 1.2% of TNF Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Virax Biolabs Group and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
TNF Pharmaceuticals	N/A	-180.71%	-84.27%

Valuation and Earnings

This table compares Virax Biolabs Group and TNF Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$84,872.00	33.38	-$6.73 million	N/A	N/A
TNF Pharmaceuticals	N/A	N/A	-$4.00 million	N/A	N/A

TNF Pharmaceuticals has lower revenue, but higher earnings than Virax Biolabs Group.

Volatility and Risk

Virax Biolabs Group has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Virax Biolabs Group and TNF Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	0	0	1	0	3.00
TNF Pharmaceuticals	0	0	0	0	0.00

Virax Biolabs Group currently has a consensus target price of $3.00, suggesting a potential upside of 242.35%. Given Virax Biolabs Group’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Virax Biolabs Group is more favorable than TNF Pharmaceuticals.

Summary

Virax Biolabs Group beats TNF Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.